Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026
Epigenetic Reactivation of <italic>SOCS-3</italic> and Inhibition of ERK1/2 Underlie Thymoquinone-Induced Apoptosis in a Chronic Myeloid Leukemia Xenograft Model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al-Rawashde Futoon Abedrabbu, Alqaraleh Moath, Hasan Diya, Elsayed Abdullrahman, Amiludin Nur Anis Ashiela Mohd, Al-Suede Fouad Saleih Resq, Al-Jamal Hamid Ali Nagi
Аннотация
OBJECTIVE: This research aimed to assess thymoquinone (TQ)'s potential to demethylate and re-express the suppressor of cytokine signaling-3 (SOCS-3) in the chronic myeloid leukemia (CML) mice model.
SUBJECT AND METHODS: A nude mouse model of CML was established, and the apoptotic influence of TQ was identified. TQ's impact on the target gene expressions was examined using real-time quantitative PCR (RT-qPCR), and SOCS-3 methylation was assessed by pyrosequencing. TQ's effects on the extracellular signal-regulated kinase 1 (ERK1) and ERK2 phosphorylation were assessed using Jess Simple Western analysis. Molecular docking of TQ's interaction with the anti-apoptotic proteins was assessed.
RESULTS: TQ exerted a marked hypomethylating influence on SOCS-3 and reduced ERK1/2 phosphorylation level in K562-xenograft tumors. TQ also significantly upregulated the apoptosis-related cysteine peptidase (Caspase-3), BCL-2-interacting mediator of cell death (Bim), p53-upregulated modulator of apoptosis (PUMA), and other apoptotic genes and downregulated B-cell lymphoma 2 (BCL-2), BCL2-like 2 (BCL-w), survivin, and X-linked inhibitor of apoptosis (XIAP) in K562 cells. TQ also exhibited marked inhibitory properties on BCL-2-related gene expressed in fetal liver (BFL-1), B-cell lymphoma-extra large (BCL-xL), myeloid cell leukemia-1 (MCL-1), and BCL-2 proteins. This led to growth inhibition and apoptosis of the K562-tumour xenograft.
CONCLUSION: These results indicate that TQ enhances CML cells' apoptosis by hypomethylating and re-expressing SOCS-3, inhibiting ERK1/2, and modulating the apoptosis-regulator gene expression and by showing consistent interaction with most of the anti-apoptotic proteins, highlighting its potential as a scaffold for designing novel inhibitors to combat CML cells.
SUBJECT AND METHODS: A nude mouse model of CML was established, and the apoptotic influence of TQ was identified. TQ's impact on the target gene expressions was examined using real-time quantitative PCR (RT-qPCR), and SOCS-3 methylation was assessed by pyrosequencing. TQ's effects on the extracellular signal-regulated kinase 1 (ERK1) and ERK2 phosphorylation were assessed using Jess Simple Western analysis. Molecular docking of TQ's interaction with the anti-apoptotic proteins was assessed.
RESULTS: TQ exerted a marked hypomethylating influence on SOCS-3 and reduced ERK1/2 phosphorylation level in K562-xenograft tumors. TQ also significantly upregulated the apoptosis-related cysteine peptidase (Caspase-3), BCL-2-interacting mediator of cell death (Bim), p53-upregulated modulator of apoptosis (PUMA), and other apoptotic genes and downregulated B-cell lymphoma 2 (BCL-2), BCL2-like 2 (BCL-w), survivin, and X-linked inhibitor of apoptosis (XIAP) in K562 cells. TQ also exhibited marked inhibitory properties on BCL-2-related gene expressed in fetal liver (BFL-1), B-cell lymphoma-extra large (BCL-xL), myeloid cell leukemia-1 (MCL-1), and BCL-2 proteins. This led to growth inhibition and apoptosis of the K562-tumour xenograft.
CONCLUSION: These results indicate that TQ enhances CML cells' apoptosis by hypomethylating and re-expressing SOCS-3, inhibiting ERK1/2, and modulating the apoptosis-regulator gene expression and by showing consistent interaction with most of the anti-apoptotic proteins, highlighting its potential as a scaffold for designing novel inhibitors to combat CML cells.